Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Dec;76(6):2286–2295. doi: 10.1172/JCI112238

Effects of thromboxane synthase inhibition on vascular responsiveness in the in vivo rat mesentery.

E K Jackson
PMCID: PMC424352  PMID: 4077980

Abstract

The purpose of this investigation was to determine the effects of thromboxane synthase inhibition on vascular responsiveness. To achieve this goal, the effects of thromboxane synthase inhibitors on mesenteric vascular responses to sympathetic nerve stimulation, norepinephrine, and angiotensin II were determined in vivo. In normotensive rats, chronic treatment with the thromboxane synthase inhibitor, UK38,485 (100 mg/kg X d X 7 d), attenuated vascular responses to nerve stimulation and angiotensin II, but not to norepinephrine. Indomethacin treatment (5 mg/kg X three doses) did not attenuate vascular responses, but did prevent chronic UK38,485 administration from attenuating vascular reactivity. A single dose of UK38,485 (100 mg/kg) did not modify vascular responses to nerve stimulation or angiotensin II, even though platelet thromboxane synthase was inhibited completely. In spontaneously hypertensive rats, chronic administration (100 mg/kg X d X 7 d) of either UK38,485, OKY1581, or U-63557A (three structurally distinct thromboxane synthase inhibitors) attenuated vascular responses to nerve stimulation and angiotensin II. Only U-63557A suppressed responses to norepinephrine. Chronic treatment with UK38,485 or U-63557A did not influence vascular reactivity in hypertensive rats treated with indomethacin. Also, chronic administration of lower doses of UK38,485 or U-63557A (30 mg/kg X d X 7 d) did not affect vascular responsiveness in hypertensive rats, despite complete blockade of platelet thromboxane synthase. These data indicate that chronic administration of high doses of thromboxane synthase inhibitors attenuates vascular responses to sympathetic nerve stimulation and angiotensin II, but not usually to norepinephrine. This action may be mediated by endoperoxide shunting within the blood vessel wall.

Full text

PDF
2286

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ardaillou N., Hagege J., Nivez M. P., Ardaillou R., Schlondorff D. Vasoconstrictor-evoked prostaglandin synthesis in cultured human mesangial cells. Am J Physiol. 1985 Feb;248(2 Pt 2):F240–F246. doi: 10.1152/ajprenal.1985.248.2.F240. [DOI] [PubMed] [Google Scholar]
  2. Blumberg A., Denny S., Nishikawa K., Pure E., Marshall G. R., Needleman P. Angiotensin III-induced prostaglandin (PG) release. Prostaglandins. 1976 Jan;11(1):195–197. doi: 10.1016/0090-6980(76)90184-2. [DOI] [PubMed] [Google Scholar]
  3. Brown C. A., Zusman R. M., Haber E. Identification of an angiotensin receptor in rabbit renomedullary interstitial cells in tissue culture. Correlation with prostaglandin biosynthesis. Circ Res. 1980 Jun;46(6):802–807. doi: 10.1161/01.res.46.6.802. [DOI] [PubMed] [Google Scholar]
  4. Cooper C. L., Shaffer J. E., Malik K. U. Mechanism of action of angiotensin II and bradykinin on prostaglandin synthesis and vascular tone in the isolated rat kidney. Effect of Ca++ antagonists and calmodulin inhibitors. Circ Res. 1985 Jan;56(1):97–108. doi: 10.1161/01.res.56.1.97. [DOI] [PubMed] [Google Scholar]
  5. Desjardins-Giasson S., Gutkowska J., Garcia R., Genest J. Effect of angiotensin ii and norepinephrine on release of prostaglandins E2 and I2 by the perfused rat mesenteric artery. Prostaglandins. 1982 Jul;24(1):105–114. doi: 10.1016/0090-6980(82)90182-4. [DOI] [PubMed] [Google Scholar]
  6. Eikenburg D. C. Functional characterization of the pre- and postjunctional alpha-adrenoceptors in the in situ perfused rat mesenteric vascular bed. Eur J Pharmacol. 1984 Oct 1;105(1-2):161–165. doi: 10.1016/0014-2999(84)90661-7. [DOI] [PubMed] [Google Scholar]
  7. FitzGerald G. A., Brash A. R., Oates J. A., Pedersen A. K. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest. 1983 Oct;72(4):1336–1343. doi: 10.1172/JCI111089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hassid A., Williams C. Vasoconstrictor-evoked prostaglandin synthesis in cultured vascular smooth muscle. Am J Physiol. 1983 Sep;245(3):C278–C282. doi: 10.1152/ajpcell.1983.245.3.C278. [DOI] [PubMed] [Google Scholar]
  10. Hedqvist P. Actions of prostacyclin (PGI2) on adrenergic neuroeffector transmission in the rabbit kidney. Prostaglandins. 1979 Feb;17(2):249–258. doi: 10.1016/0090-6980(79)90045-5. [DOI] [PubMed] [Google Scholar]
  11. Hedqvist P. Basic mechanisms of prostaglandin action on autonomic neurotransmission. Annu Rev Pharmacol Toxicol. 1977;17:259–279. doi: 10.1146/annurev.pa.17.040177.001355. [DOI] [PubMed] [Google Scholar]
  12. Hemker D. P., Aiken J. W. Actions of indomethacin and prostaglandins E2 and D2 on nerve transmission in the nictitating membrane of the cat. Prostaglandins. 1981 Oct;22(4):599–611. doi: 10.1016/0090-6980(81)90069-1. [DOI] [PubMed] [Google Scholar]
  13. Hemker D. P., Aiken J. W. Modulation of autonomic neurotransmission by PGD2: comparison with effects of other prostaglandins in anesthetized cats. Prostaglandins. 1980 Aug;20(2):321–332. doi: 10.1016/s0090-6980(80)80050-5. [DOI] [PubMed] [Google Scholar]
  14. Jackson E. K., Campbell W. B. A possible antihypertensive mechanism of propranolol: antagonism of angiotensin II enhancement of sympathetic nerve transmission through prostaglandins. Hypertension. 1981 Jan-Feb;3(1):23–33. doi: 10.1161/01.hyp.3.1.23. [DOI] [PubMed] [Google Scholar]
  15. Jackson E. K., Campbell W. B. The in situ blood perfused rat mesentery; a model for assessing modulation of adrenergic neurotransmission. Eur J Pharmacol. 1980 Aug 29;66(2-3):217–224. doi: 10.1016/0014-2999(80)90145-4. [DOI] [PubMed] [Google Scholar]
  16. Jackson E. K., Uderman H. D., Herzer W. A., Branch R. A. Attenuation of noradrenergic neurotransmission by the thromboxane synthetase inhibitor, UK 38,485. Life Sci. 1984 Jul 9;35(2):221–228. doi: 10.1016/0024-3205(84)90143-7. [DOI] [PubMed] [Google Scholar]
  17. Konieczkowski M., Dunn M. J., Stork J. E., Hassid A. Glomerular synthesis of prostaglandins and thromboxane in spontaneously hypertensive rats. Hypertension. 1983 Jul-Aug;5(4):446–452. doi: 10.1161/01.hyp.5.4.446. [DOI] [PubMed] [Google Scholar]
  18. Maguire E. D., Wallis R. B. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat. Thromb Res. 1983 Oct 1;32(1):15–27. doi: 10.1016/0049-3848(83)90150-0. [DOI] [PubMed] [Google Scholar]
  19. Makita Y. Effects of prostaglandin I2 and carbocyclic thromboxane A2 on smooth muscle cells and neuromuscular transmission in the guinea-pig mesenteric artery. Br J Pharmacol. 1983 Mar;78(3):517–527. doi: 10.1111/j.1476-5381.1983.tb08811.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Needleman P., Wyche A., Raz A. Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest. 1979 Feb;63(2):345–349. doi: 10.1172/JCI109309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Patrignani P., Filabozzi P., Catella F., Pugliese F., Patrono C. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism. J Pharmacol Exp Ther. 1984 Feb;228(2):472–477. [PubMed] [Google Scholar]
  22. Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366–1372. doi: 10.1172/JCI110576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., Satta M. A., Peskar B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980 Feb 1;17(3-4):317–327. doi: 10.1016/0049-3848(80)90066-3. [DOI] [PubMed] [Google Scholar]
  24. Pipili E., Poyser N. L. Effects of nerve stimulation and of administration of noradrenaline or potassium chloride upon the release of prostaglandins, I2, E2, and F2 alpha from te perfused mesenteric arterial bed of the rabbit. Br J Pharmacol. 1981 Jan;72(1):89–93. doi: 10.1111/j.1476-5381.1981.tb09109.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Schwartzman M., Liberman E., Raz A. Bradykinin and angiotensin II activation of arachidonic acid deacylation and prostaglandin E2 formation in rabbit kidney. Hormone-sensitive versus hormone-insensitive lipid pools of arachidonic acid. J Biol Chem. 1981 Mar 10;256(5):2329–2333. [PubMed] [Google Scholar]
  26. Shibouta Y., Terashita Z. I., Inada Y., Nishikawa K., Kikuchi S. Enhanced thromboxane A2 biosynthesis in the kidney of spontaneously hypertensive rats during development of hypertension. Eur J Pharmacol. 1981 Mar 26;70(3):247–256. doi: 10.1016/0014-2999(81)90157-6. [DOI] [PubMed] [Google Scholar]
  27. Timimi K. S., Bedwani J. R., Stanton T. W. Effects of prostaglandin E2 and a prostaglandin endoperoxide analogue on neuroeffector transmission in the rat anococcygeus msucle. Br J Pharmacol. 1978 May;63(1):167–176. doi: 10.1111/j.1476-5381.1978.tb07786.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Uderman H. D., Workman R. J., Jackson E. K. Attenuation of the development of hypertension in spontaneously hypertensive rats by the thromboxane synthetase inhibitor, 4'-(imidazol-1-yl) acetophenone. Prostaglandins. 1982 Aug;24(2):237–244. doi: 10.1016/0090-6980(82)90149-6. [DOI] [PubMed] [Google Scholar]
  29. Viinikka L., Ylikorkala O. Measurement of thromboxane B2 in human plasma or serum by radioimmunoassay. Prostaglandins. 1980 Oct;20(4):759–766. doi: 10.1016/0090-6980(80)90114-8. [DOI] [PubMed] [Google Scholar]
  30. Weitzell R., Steppeler A., Starke K. Effects of prostaglandin E2, prostaglandin I2 and 6-keto-prostaglandin F1 alpha on adrenergic neurotransmission in the pulmonary artery of the rabbit. Eur J Pharmacol. 1978 Nov 1;52(1):137–141. doi: 10.1016/0014-2999(78)90033-x. [DOI] [PubMed] [Google Scholar]
  31. Wennmalm A. Prostaglandin-mediated inhibition of noradrenaline release: V. A comparison of the neuroinhibitory effect of three prostaglandins: E2, I2, and 6-keto-PGF1alpha. Prostaglandins Med. 1978 Jul;1(1):49–54. doi: 10.1016/0161-4630(78)90076-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES